Evidence map›Paper›PMID 28733266›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

Matthew G Mei, Thai M Cao, Lu Chen, Joo Y Song, Tanya Siddiqi, Ji-Lian Cai, Leonardo T Farol, Monzr M Al Malki, Amandeep Salhotra, Ibrahim Aldoss and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.International journal of molecular sciences · 2019
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Matthew G MeiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Thai M CaoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California; Kaiser Permanente Southern California Bone Marrow Transplantation Program, Los Angeles, California.
Lu ChenDepartment of Information Sciences, City of Hope National Medical Center, Duarte, California.
Joo Y SongDepartment of Pathology, City of Hope National Medical Center, Duarte, California.
Tanya SiddiqiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Ji-Lian CaiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California; Kaiser Permanente Southern California Bone Marrow Transplantation Program, Los Angeles, California.
Leonardo T FarolDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California; Kaiser Permanente Southern California Bone Marrow Transplantation Program, Los Angeles, California.
Monzr M Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Ibrahim AldossDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Joycelynne PalmerDepartment of Information Sciences, City of Hope National Medical Center, Duarte, California.
Alex F HerreraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Jasmine ZainDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Leslie L PopplewellDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Robert W ChenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Steven T RosenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Larry KwakDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Auayporn P NademaneeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Lihua E BuddeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. Electronic address: ebudde@coh.org.
City Of Hope National Medical Center · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
NCI NIH HHS P30 CA033572NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

High-dose therapy followed by autologous stem cell transplantation (ASCT) can improve outcomes for mantle cell lymphoma (MCL) but is associated with a high incidence of relapse. A retrospective study of 191 MCL patients who underwent ASCT at City of Hope was performed to examine prognostic factors for outcomes after ASCT. For all patients the 5-year overall survival (OS) was 71% (95% confidence interval [CI], 63% to 77%) and progression-free survival (PFS) was 53% (95% CI, 45% to 60%). The 5-year cumulative incidence of relapse was 41% (95% CI, 34% to 48%) with a continuous pattern of relapse events occurring at a median of 2.1 years (range, .2 to 13.4) after ASCT. In multivariate analysis, post-transplant maintenance rituximab was the factor most significantly associated with both OS (relative risk [RR], .17; 95% CI, .07 to .38) and PFS (RR, .25; 95% CI, .14 to .44). For the subset of patients who had positron emission tomography (PET) data available and were in a PET-negative first complete remission at ASCT (n = 105), maintenance rituximab was significantly associated with superior OS (RR, .17; 95% CI, .05 to .59) and PFS (RR, .20; 95% CI, .09 to .43). These results support a benefit with maintenance rituximab for all MCL patients treated with ASCT.

Indexed as

AdultAgedAntineoplastic Agents, ImmunologicalFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Mantle-CellMaleMiddle AgedRituximabSurvival RateTransplantation, AutologousAntineoplastic Agents, ImmunologicalRituximabAutologous hematopoietic cell transplantationLymphomaMantle cellRituximab

Identifiers

PMID28733266
PMCPMC5870870
OpenAlexW2738707626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.